Kite Pharma, Inc. develops novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. In addition, it engages in developing T cell receptor-based therapies that target self-antigens, viral antigens, and neo-antigens. The company was incorporated in 2009 and is based in Santa Monica, California with additional locations in Santa Monica, El Segundo, Oceanside, Emeryville, California; Frederick, Maryland; United Kingdom; and the Netherlands. Kite Pharma, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Metrics to compare | KITE | Peers Peers - average of corresponding metrics from companies closely matching KITE: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKITEPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |